Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACORES-2: RAS blocker discontinuation in COVID-19
NCT04329195Phase 3Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2020
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Time to clinical improvement from day 0 to day 28. Started Apr 2020; status: terminated.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04329195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04329195.